Funding cuts have disrupted ongoing efforts in Botswana to liberate patients, particularly children, from dependence on antiretroviral therapy (ART). For over two decades, Roger Shapiro has worked to decrease HIV infection rates and improve health outcomes in the region. His recent trial focuses on a novel treatment using broadly neutralizing antibodies (bNAbs), which may allow some children to achieve viral control post-treatment. Despite previous challenges in vaccine development, Shapiro's research represents a significant advancement in the fight against HIV, aiming for a potential cure for pediatric patients.
Shapiro's trial aims to find a new treatment option by examining the effects of a combination of three broadly neutralizing HIV antibodies. The research builds upon previous studies suggesting that bNAbs might help the immune system clear the virus better than standard ART.
'It is the only study in pediatrics looking at three antibodies as combination treatment for HIV and ultimately as a path toward HIV cure,' said Shapiro, a professor of immunology and infectious diseases at the Chan School.
Collection
[
|
...
]